Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.

Becker, Charlotte LU ; Piironen, Timo ; Pettersson, Kim ; Hugosson, Jonas and Lilja, Hans LU orcid (2003) In Journal of Urology 170(4 Pt 1). p.1169-1174
Abstract
Purpose: We investigated the value of serum measurements for glandular kallikrein 2 (hK2), and free (f) and total (t) prostate specific antigen (PSA) in a second round of biannual screening for prostate cancer. Materials and Methods: In 1995 to 1996, 5,853 of 9,811 randomly selected men in Goteborg, Sweden 50 to 66 years old had PSA measurements. Of 660 men 611 with tPSA 3 ng/ml or greater underwent biopsy and 145 had cancer. All were re-invited 2 years later for PSA testing, and 506 of 596 men with tPSA 3 ng/ml or greater underwent biopsy and 113 cancers were detected. We analyzed hK2, tPSA and fPSA in 423 of 453 (93%) men who underwent biopsy in 1997 to 1998 who were also screened in 1995 to 1996. Results: The 99 of 423 (23%) men who... (More)
Purpose: We investigated the value of serum measurements for glandular kallikrein 2 (hK2), and free (f) and total (t) prostate specific antigen (PSA) in a second round of biannual screening for prostate cancer. Materials and Methods: In 1995 to 1996, 5,853 of 9,811 randomly selected men in Goteborg, Sweden 50 to 66 years old had PSA measurements. Of 660 men 611 with tPSA 3 ng/ml or greater underwent biopsy and 145 had cancer. All were re-invited 2 years later for PSA testing, and 506 of 596 men with tPSA 3 ng/ml or greater underwent biopsy and 113 cancers were detected. We analyzed hK2, tPSA and fPSA in 423 of 453 (93%) men who underwent biopsy in 1997 to 1998 who were also screened in 1995 to 1996. Results: The 99 of 423 (23%) men who underwent biopsy diagnosed with prostate cancer in 1997 to 1998 had significantly different tPSA, percent fPSA and hK2 x tPSA/fPSA compared to the men with negative biopsies from 2 years earlier. The largest area under curve was obtained for hK2 x tPSA/fPSA in serum from 1995 to 1996 and from 1997 to 1998, but the difference was not significant compared to tPSA and percent fPSA. In serum from 1997 to 1998 measurements of hK2 x tPSA/fPSA gave significantly higher specificity than tPSA at 85% sensitivity, and significantly higher specificity than tPSA and percent fPSA at 70% to 75% sensitivity. In addition, levels of hK2 and hK2 x tPSA/fPSA manifested a significantly greater 2-year increase in men with cancer compared to those with benign biopsies. Conclusions: In men with tPSA levels 3.0 ng/ml or greater who were not diagnosed with cancer during a first round of screening, hK2 measurements enhanced specificity compared to tPSA testing at moderately high sensitivity, and manifested a greater 2-year increase in men with cancer. (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
tissue kallikreins, prostate-specific antigen, diagnosis, prostatic neoplasms
in
Journal of Urology
volume
170
issue
4 Pt 1
pages
1169 - 1174
publisher
Lippincott Williams & Wilkins
external identifiers
  • wos:000185401200024
  • pmid:14501718
  • scopus:0043194049
  • pmid:14501718
ISSN
1527-3792
DOI
10.1097/01.ju.0000086640.19892.0b
language
English
LU publication?
yes
id
6bce786b-c284-4ad2-ac52-27816ee12b16 (old id 118443)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14501718&dopt=Abstract
date added to LUP
2016-04-01 16:24:33
date last changed
2022-04-30 21:08:05
@article{6bce786b-c284-4ad2-ac52-27816ee12b16,
  abstract     = {{Purpose: We investigated the value of serum measurements for glandular kallikrein 2 (hK2), and free (f) and total (t) prostate specific antigen (PSA) in a second round of biannual screening for prostate cancer. Materials and Methods: In 1995 to 1996, 5,853 of 9,811 randomly selected men in Goteborg, Sweden 50 to 66 years old had PSA measurements. Of 660 men 611 with tPSA 3 ng/ml or greater underwent biopsy and 145 had cancer. All were re-invited 2 years later for PSA testing, and 506 of 596 men with tPSA 3 ng/ml or greater underwent biopsy and 113 cancers were detected. We analyzed hK2, tPSA and fPSA in 423 of 453 (93%) men who underwent biopsy in 1997 to 1998 who were also screened in 1995 to 1996. Results: The 99 of 423 (23%) men who underwent biopsy diagnosed with prostate cancer in 1997 to 1998 had significantly different tPSA, percent fPSA and hK2 x tPSA/fPSA compared to the men with negative biopsies from 2 years earlier. The largest area under curve was obtained for hK2 x tPSA/fPSA in serum from 1995 to 1996 and from 1997 to 1998, but the difference was not significant compared to tPSA and percent fPSA. In serum from 1997 to 1998 measurements of hK2 x tPSA/fPSA gave significantly higher specificity than tPSA at 85% sensitivity, and significantly higher specificity than tPSA and percent fPSA at 70% to 75% sensitivity. In addition, levels of hK2 and hK2 x tPSA/fPSA manifested a significantly greater 2-year increase in men with cancer compared to those with benign biopsies. Conclusions: In men with tPSA levels 3.0 ng/ml or greater who were not diagnosed with cancer during a first round of screening, hK2 measurements enhanced specificity compared to tPSA testing at moderately high sensitivity, and manifested a greater 2-year increase in men with cancer.}},
  author       = {{Becker, Charlotte and Piironen, Timo and Pettersson, Kim and Hugosson, Jonas and Lilja, Hans}},
  issn         = {{1527-3792}},
  keywords     = {{tissue kallikreins; prostate-specific antigen; diagnosis; prostatic neoplasms}},
  language     = {{eng}},
  number       = {{4 Pt 1}},
  pages        = {{1169--1174}},
  publisher    = {{Lippincott Williams & Wilkins}},
  series       = {{Journal of Urology}},
  title        = {{Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.}},
  url          = {{http://dx.doi.org/10.1097/01.ju.0000086640.19892.0b}},
  doi          = {{10.1097/01.ju.0000086640.19892.0b}},
  volume       = {{170}},
  year         = {{2003}},
}